Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: lung cancer + cancer drug + cancer  Related to the article below (Last Update: 8/4/2008)

YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC ...
FOXBusiness -
We intend to file for registration trials in 2008 for patients with non small cell lung cancer (NSCLC) and for those with brain metastases because of ...YMI - OTC:CMTX
Gene Test Leads To Targeted Cancer Treatment
cbs4denver.com, CO -
Dr. Yong Chen was diagnosed with advanced lung cancer in February of this year. He tested positive on the gene screening and was given the extra drug, ...
OXiGENE Reports Second Quarter 2008 Results
MarketWatch - Aug 3, 2008
... bevacizumab for the treatment of Non-Small Cell Lung Cancer, as well as the management of other ongoing clinical trials and drug development activities. ...
Craig W. Philips Takes Helm at CTI
Trading Markets (press release), CA -
In addition CTI has submitted an application for approval to market its lung cancer drug candidate OPAXIO in Europe and expects to receive a response from ...CTIC - OTC:CMTX

Washington Post
Business Glance
Salt Lake Tribune, United States - 48 minutes ago
The New York-based companies are partners on the colon- and head-and-neck-cancer treatment Erbitux. They are also developing the drug as a lung cancer ...
ImClone calls Bristol offer too low Reuters
Icahn Calls Bristol Bid Too Low, Weighs ImClone Split (Update2) Bloomberg
Patience Might Have Paid Off New York Times
Wall Street Journal Blogs - Forbes
all 733 news articles »  IMCL - BMY
Cell phone use, cancer risk unknown; memo raises alarm
El Paso Times, TX - Aug 3, 2008
"We weren't sure about smoking and lung cancer. They had to make a recommendation based on knowledge that wasn't complete. Once it was, we had trouble ...
Drug shows promise treating breast cancer
St. Louis Post-Dispatch,  United States -
Her mother died of the disease in 1997, and her father died of lung cancer just four months earlier. The chance of preventing a recurrence was important to ...
Nastech Pharmaceutical Company Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
Our effort to develop a drug candidate against lung cancer permits us to advance our platform on two fronts; one, administration of an RNAi, DI pulmonary ...MRNA
Infinity Highlights Clinical Advances in Its Portfolio of Anti ...
MarketWatch -
IPI-504 is also being evaluated in the Phase 2 portion of a Phase 1/2 study in patients with advanced non-small cell lung cancer (NSCLC). ...INFI
Asian Herb Inspires Cancer Drug
NewsMax.com, FL -
In laboratory research, honokiol looks promising for use in treating breast, lung, and bladder cancer. ?Knowing more about how honokiol works will tell us ...
Source: Google News

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line -
SP Cole, G Bhardwaj, JH Gerlach, JE Mackie, CE … - Science, 1992 - sciencemag.org
... J. Biol. Chem. 280: 6231-6237 | Abstract ? | Full Text ? | PDF ? RLIP76 Transports
Vinorelbine and Mediates Drug Resistance in Non-Small Cell Lung Cancer. ...

… Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer -
M Fukuoka, S Yano, G Giaccone, T Tamura, K … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib
250 ... LUNG CANCER is the most common cause of cancer deaths in both men and ...

… Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer A Randomized Trial -
MG Kris, RB Natale, RS Herbst, TJ Lynch, D Prager, … - JAMA, 2003 - Am Med Assoc
... patients will benefit from gefitinib is to administer the drug and observe its ... The
pathobiology of growth-factor signaling in lung cancer may be fundamentally ...

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy -
JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S … - Science, 2004 - sciencemag.org
... in Non-Small Cell Lung Cancer. Oncologist 10: 467-470 [Full Text]; Cohen, MH, Johnson,
JR, Chen, YF, Sridhara, R., Pazdur, R. (2005). FDA Drug Approval Summary ...

… Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy 1 -
RA Olie, AP Simoes-Wust, B Baumann, SH Leech, D … - Cancer Research, 2000 - AACR
... lung cancer (1) . The expression of survivin in tumors is correlated with drug
resistance and/or shorter survival of patients with non-small cell lung cancer ( ...

… and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a … -
T Le Chevalier, D Brisgand, JY Douillard, JL Pujol … - Journal of Clinical Oncology, 1994 - jco.ascopubs.org
... and JP Pignon Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy
Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis JAMA, July ...

… the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer … -
GJ Zaman - Cancer Research, 1993 - AACR
... ARTICLES. Analysis of the expression of MRP, the gene for a new putative transmembrane
drug transporter, in human multidrug resistant lung cancer cell lines. ...

EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib -
S Kobayashi, TJ Boggon, T Dayaram, PA Janne, O … - New England Journal of Medicine, 2005 - content.nejm.org
... stromal tumors, suggest that when a relapse occurs in patients with anilinoquinazoline-
responsive lung cancer with a drug-susceptibility mutation, the tumor ...

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways -
R Sordella, DW Bell, DA Haber, J Settleman - Science, 2004 - sciencemag.org
... (D) The H1650 and H1975 lung cancer cell lines, which express endogenous EGFR kinase
domain mutations, exhibit comparably increased drug sensitivity with ...

… cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug … -
T Sethi, RC Rintoul, SM Moore, AC MacKinnon, D … - Nature Medicine, 1999 - nature.com
... Extracellular matrix proteins protect small cell lung cancer cells against apoptosis:
A mechanism for small cell lung cancer growth and drug resistance in vivo. ...

Source: Google Scholar
 
 

Cancer drug helps early lung cancer patients

Last Updated: 2006-12-14 15:07:53 -0400 (Reuters Health)

WASHINGTON - A drug that starves tumors of their blood supply can help patients live longer, without adding to some of the worst effects of chemotherapy, researchers reported on Thursday.

They said Avastin helped patients live a median of two months longer -- a significant time for lung cancer, which usually kills quickly after it is diagnosed.Also, more patients were helped by chemotherapy when Avastin was added, they reported in this week's issue of the New England Journal of Medicine.

"This is great news for lung cancer patients -- they live longer, and the side effects from Avastin are unlike those of conventional chemotherapy. For example, Avastin does not cause hair loss, nausea, or vomiting," said Dr. Joan Schiller, chief of hematology/oncology at the University of Texas Southwestern Medical Center, who led the trial.

Article continues below and (thank you)
 

The researchers added Avastin to standard chemotherapy in a trial of 878 patients with non-small-cell lung cancer.

This is the most common form of lung cancer, which will kill an estimated 162,460 people in the United States alone in 2006.

Lung cancer usually does not cause symptoms until it is far advanced, and only 5 percent of patients survive.

But treatment can help them live longer, and reduce the amount of time they suffer pain and discomfort from the tumors.

Schiller's team tried adding Avastin, known generically as bevacizumab, to the standard chemotherapy regime of paclitaxel and carboplatin, which are infused intravenously.

Avastin, developed by San Francisco-based Genentech and sold by Roche, is an anti-angiogenic drug, which means it stops tumors from growing blood vessels to feed themselves. It is a monoclonal antibody, a human protein that is genetically engineered to interfere with the proteins that cells use to make blood vessels.

"Twenty years ago, we thought no treatment could help patients with advanced lung cancer," Schiller said in a statement.

"Now, we are finding out that this very unique drug called Avastin can also help improve survival even more. Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better."

Avastin seems to enhance the chemo, she said.

"In addition to choking off the tumor blood supply, Avastin also makes the remaining blood vessels healthier and enables them to diffuse the chemo drugs into the tumor better," she said.

Unlike the men in the trial, the women did not, as a group, live any longer with Avastin, a finding that could be "a fluke", Schiller said. More study was planned.

Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page